Source comparison
Does Tesamorelin Help Visceral Fat Reduction Research: Comparison
Tesamorelin 2mg daily GHRH analogue → pituitary GH release → HSL activation in visceral adipocytes 15–20% (CT-confirmed) Minimal (4–8%) Regains 60–70% within 12 weeks off-treatment Gold standard for GH-mediated VAT reduction. Mechanism is specific, reproducibl
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- GHRH analogue → pituitary GH release → HSL activation in visceral adipocytes
- 15–20% (CT-confirmed)
- Minimal (4–8%)
- Regains 60–70% within 12 weeks off-treatment
- Gold standard for GH-mediated VAT reduction. Mechanism is specific, reproducible, and non-suppressive to endogenous secretion
- rhGH (recombinant human growth hormone) 2–4 IU daily
- Direct exogenous GH → systemic lipolysis
- 10–15%
- Moderate (10–15%)
- Regains 50–60% within 8 weeks; risk of pituitary suppression
- Broader lipolytic effect but suppresses natural GH production. Less selective for VAT, higher glucose dysregulation risk
- Caloric deficit (500 kcal/day) + resistance training
- Energy imbalance → lipolysis; muscle retention via training stimulus
- 8–12%
- High (15–25%)
- Maintained if deficit sustained; typically regains without continued adherence
- Most sustainable long-term but achieves lower VAT-specific reduction. Subcutaneous fat responds more readily to caloric restriction
- Metformin 2000mg daily (off-label for VAT in metabolic syndrome)
- AMPK activation → improved insulin sensitivity; indirect lipolysis
- 3–6%
- Minimal (2–4%)
- Partially maintained if continued; regains 40–50% within 6 months off-treatment
- Insulin-sensitising effect supports metabolic health but VAT reduction is secondary and modest compared to GH-based therapies